Fig. 4

FASN inhibition increases sensitivity of melanoma cell lines to clinical ROS inducers. a Real time cell growth analysis of D10 BMR cells (n = 3) treated with DT, TVB-3664 and hydrogen peroxide, piperazine erastin or RSL3. Two-way ANOVA with Tukey’s multiple comparisons. b Real time cell growth analysis of D10 BMR cells treated with DT, TVB-3664 in combination with 2-methoxyestradiol (n = 2), atovaquone (n = 2), beta-lapachone (n = 2), crizotinib (n = 2), elesclomol (n = 2), proguanil hydrochloride (n = 3) or ATO (n = 3). Two-way ANOVA with Tukey’s multiple comparisons. c-e Cellular ROS, mitochondrial superoxide and oxidized C11 BODIPY levels as a surrogate of lipid peroxidation degree in D10 BMR cells (n = 6) treated with DT, ATO and TVB-3664 at 120 h. f-g Real time cell growth analysis of D10 BMR cells treated with DT, TVB-3664 and ATO, in combination with oleate (n = 12), PUFA (n = 9), ferrostatin-1 (n = 15) or ZVAD (n = 15). Two-way ANOVA with Tukey’s multiple comparisons. Data represent mean ± SEM of biologically independent samples. (*p < 0.05, ***p < 0.001, ****p < 0.0001)